 "Strides Shasun to divest UK arm for Rs 240 crore")
The board of directors of Strides Shasun Ltd has approved the divestment of the UK-based Shasun Pharma Solutions Ltd (SPSL), which is into CRAMS API business, to the current management team of SPSL with funding by the promoter group of Strides Shasun for an enterprise value of GBP 25 million (about Rs 240 crore).
The erstwhile Shasun Pharmaceuticals Ltd acquired SPSL in 2006 from Rhodia. In 2011, this business had a major setback due to failure of a key customer product in market place and the business could not sustain profitability for several years.
Since 2014, under the new management team, SPSL shifted focus from a pure CRAMS player to multiple industry CRAMS business including services. The efforts are taking time and the business is in the process of reaching stable operation.
In FY16, SPSL achieved an EBITDA of GBP 3.94 mn (about Rs 38 crore).
The erstwhile Shasun Pharmaceuticals Ltd acquired SPSL in 2006 from Rhodia. In 2011, this business had a major setback due to failure of a key customer product in market place and the business could not sustain profitability for several years.
Since 2014, under the new management team, SPSL shifted focus from a pure CRAMS player to multiple industry CRAMS business including services. The efforts are taking time and the business is in the process of reaching stable operation.
In FY16, SPSL achieved an EBITDA of GBP 3.94 mn (about Rs 38 crore).
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%